PTC Therapeutics, Inc. (PTCT)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, PTC Therapeutics, Inc. currently loses $14.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
PTC Therapeutics’ revenue topped consensus in the third fiscal quarter of 2026, based on preliminary results reported October 29, 2026, with revenue up 69.6% year over year to about $357.8 million. On the quarter’s consensus comparison, revenue of $357.8 million topped the $306.4 million estimate (+16.8%), rising from $211.0 million a year ago. Profitability was positive at the operating line, with operating income of roughly $25.1 million, while cash generation was negative, with negative operating cash flow of about $25.3 million. Consensus for the next period calls for EPS of $0.30 on revenue of $323.2 million.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. develops and commercializes medicines for rare genetic disorders as a biotechnology company listed on the NASDAQ Global Select Market under PTCT. Its portfolio spans approved and partnered therapies as well as pipeline programs, and it recorded $1.7 billion in revenue in FY2025.
Today's Snapshot
PTCT closed slightly lower at 60.23, while its sector was weaker. The day ended with PTCT within 2.4% of its 52-week low of 58.80.
Trading Volume
Below 10d avg (787.3K)
627.3K
vs S&P 500 Today
Inline with Market
+0.04%
Updated: November 18, 2026 at 21:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$62.52 - $69.41Sell
- RSI (14)41.19Neutral
- Stochastic %K (14, 3, 3)13.91Buy
- MACD Level (12, 26)-0.56Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.